Ipilimumab, Nivolumab, and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Clinical Trial ID NCT01896999

PubWeight™ 9.29‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01896999

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 2014 1.22
2 Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology 2015 1.06
3 Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". Toxins (Basel) 2014 0.92
4 Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. Hum Vaccin Immunother 2016 0.89
5 The past, present and future of immunotherapy against tumor. Transl Lung Cancer Res 2015 0.85
6 Customized targeted therapy in Hodgkin lymphoma: hype or hope? Hematol Oncol Clin North Am 2014 0.82
7 Oncogene withdrawal engages the immune system to induce sustained cancer regression. J Immunother Cancer 2014 0.80
8 Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet? Bone Marrow Transplant 2015 0.77
9 Relapsed Hodgkin lymphoma: management strategies. Curr Hematol Malig Rep 2014 0.76
10 Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. Lancet Haematol 2020 0.75
11 Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era. Hematology Am Soc Hematol Educ Program 2014 0.75
12 Recent advances in the management of Hodgkin lymphoma. F1000Res 2016 0.75
Next 100